---
layout: post
title: "Using Artificial Intelligence and Machine Learning in the Development of Drug and Biological Products; Availability"
date: 2026-02-05 18:55:31 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-09985
original_published: 2023-05-11 00:00:00 +0000
significance: 8.00
---

# Using Artificial Intelligence and Machine Learning in the Development of Drug and Biological Products; Availability

**Published:** February 05, 2026 18:55 UTC
**Source:** Federal Register
**Original Published:** May 11, 2023 00:00 UTC
**Document Number:** 2023-09985

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the publication of a discussion paper entitled "Using Artificial Intelligence and Machine Learning in the Development of Drug and Biological Products." To fulfill its mission of protecting, promoting, and advancing public health, FDA's Center for Drug Evaluation and Research (CDER), in collaboration with the Center for Biologics Evaluation and Research (CBER) and Center for Devices and Radiological Health (CDRH), including the Digital Health Center of Excellence (DHCoE), is issuing this document to facilitate a discussion with stakeholders on the use of artificial intelligence (AI) and machine learning (ML) in drug development to help inform the regulatory landscape in this area.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/05/11/2023-09985/using-artificial-intelligence-and-machine-learning-in-the-development-of-drug-and-biological)
- API: https://www.federalregister.gov/api/v1/documents/2023-09985

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
